Dermatitis, Atopic
Showing 1 - 25 of 2,245
Atopic Dermatitis Trial (Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose)
Not yet recruiting
- Atopic Dermatitis
- Dupilumab - Discontinuation
- +2 more
- (no location specified)
Nov 2, 2023
Atopic Dermatitis Trial (Cosmetic Product TOPIALYSE Baume Protect+)
Not yet recruiting
- Atopic Dermatitis
- Cosmetic Product TOPIALYSE Baume Protect+
- (no location specified)
Oct 25, 2023
Dermatitis, Atopic Trial (Monoclonal antibody BAT6026, sodium chloride injection)
Not yet recruiting
- Dermatitis, Atopic
- Monoclonal antibody BAT6026
- sodium chloride injection
- (no location specified)
Oct 19, 2023
Atopic Dermatitis Trial (CM310)
Not yet recruiting
- Atopic Dermatitis
- CM310
- (no location specified)
Oct 30, 2023
Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp Trial (HY209GEL Active, Placebo)
Not yet recruiting
- Atopic Dermatitis
- +2 more
- HY209GEL Active
- Placebo
- (no location specified)
Aug 31, 2023
Atopic Dermatitis Trial in Helsinki (Nature-based exposure by biodiversity component in lotion., Placebo group using colored
Active, not recruiting
- Atopic Dermatitis
- Nature-based exposure by biodiversity component in lotion.
- Placebo group using colored lotion.
-
Helsinki, FinlandUute Scientific Oy
Nov 8, 2023
Insulin Resistance in Atopic Dermatitis Patients
Recruiting
- Atopic Dermatitis
-
Istanbul, TurkeyBezmialem Vakif University Hospital
Jun 6, 2023
Atopic Dermatitis, Eczema Trial run by the National Institute of Allergy and Infectious Diseases (NIAID) (Roseomonas mucosa
Not yet recruiting
- Atopic Dermatitis
- Eczema
- Roseomonas mucosa (RSM2015) and Cardamom seeds
- Placebo (sucrose)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Oct 27, 2023
Moderate to Severe Atopic Dermatitis Trial (SHR-1819 injection)
Not yet recruiting
- Moderate to Severe Atopic Dermatitis
- SHR-1819 injection
- (no location specified)
Aug 22, 2023
Atopic Dermatitis, Eczema Trial (Lebrikizumab)
Not yet recruiting
- Atopic Dermatitis
- Eczema
- Lebrikizumab
- (no location specified)
Aug 7, 2023
Atopic Dermatitis Trial in Shanghai (MG-K10/Placebo)
Active, not recruiting
- Atopic Dermatitis
- MG-K10/Placebo
-
Shanghai, ChinaHuashan Hospital Affiliated to Fudan University
Aug 31, 2023
Atopic Dermatitis Trial in Hellerup (flexible patient centred consultations)
Recruiting
- Atopic Dermatitis
- flexible patient centred consultations
-
Hellerup, Copenhagen, DenmarkGentofte University Hospital
Sep 4, 2023
Topical Cannabidiol (CBD) Products for Atopic Dermatitis
Recruiting
- Atopic Dermatitis
- Phoilex Releaf Gel
-
Brampton, Ontario, CanadaPhoenix Medical Spa X Peak Human
Aug 28, 2023
Dupilumab in Participants =6 Years With Atopic Dermatitis
Recruiting
- Atopic Dermatitis
-
Berlin, GermanyInvestigational Site Number :
Sep 18, 2023
Atopic Dermatitis Trial in Roma (Upadacitinib)
Recruiting
- Atopic Dermatitis
- Upadacitinib
-
Roma, ItalyIrccs Fondazione Policlinico Gemelli
Aug 4, 2023
Atopic Dermatitis Trial in Nice (Blood sample)
Not yet recruiting
- Atopic Dermatitis
- Blood sample
-
Nice, FranceNice University Hospital
May 11, 2023
ElidelĀ® in South and East Asian Pediatric Atopic Dermatitis.
Not yet recruiting
- Mild to Moderate Atopic Dermatitis
- Elidel 1% Topical Cream
- (no location specified)
Sep 18, 2023
Dermatitis Atopic Trial in Lafayette (Amlitelimab, Placebo, Topical corticosteroids)
Recruiting
- Dermatitis Atopic
- Amlitelimab
- +3 more
-
Lafayette, CaliforniaSunwise Clinical Research Site Number : 8401022
Nov 8, 2023
Atopic Dermatitis Trial in Beijing (LNK01001 Dose A, LNK01001 Dose B, )
Completed
- Atopic Dermatitis
- LNK01001 Dose A
- +2 more
-
Beijing, ChinaJianzhong Zhang
Oct 10, 2023
Atopic Dermatitis Trial in Beijing (GD-iExo-001, normal saline)
Recruiting
- Atopic Dermatitis
- GD-iExo-001
- normal saline
-
Beijing, Beijing, ChinaChinese Academy of Medical Science & Peking Union Medical Colleg
Jul 23, 2023
Atopic Dermatitis Trial (SAR444656 (KT-474), Placebo)
Not yet recruiting
- Atopic Dermatitis
- SAR444656 (KT-474)
- Placebo
- (no location specified)
Sep 21, 2023